SECURITIES
AND EXCHANGE COMMISSION


Washington,
D.C. 20549





FORM
10-Q








(Mark
One)





[ X
]QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934





For the
quarterly period ended September 30, 2008





OR





[    ]TRANSITION REPORT UNDER SECTION 13 OF
15(d) OF THE EXCHANGE ACT OF 1934





From the
transition period from ___________ to ____________.





Commission
File Number 000-51750





TRIPLE A MEDICAL,
INC.


(Exact
name of small business issuer as specified in its charter)





Nevada
            
            20-4846807(State
      or other jurisdiction of incorporation or organization)
            
            (IRS
      Employer Identification No.)





604 Creekview, Ovilla, Texas
75154


(Address
of principal executive offices)





(800)
843-8179


(Issuer's
telephone number)




N/A (Former name, former address and former
fiscal year, if changed since last report)





Indicate by check mark whether the
registrant (1) filed all reports required to be filed by Section 13 or 15(d) of
the Exchange Act during the past 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days:.  Yes [ X
]   No [     ].





Indicate
by a check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of “large accelerated filer,” ”accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act.





Large
      Accelerated Filer [  ]
            
            Accelerated
      Filer [  ]Non-Accelerated
      Filer [    ].
            
            Smaller
      Reporting Company [X]





Indicate
by a check mark whether the company is a shell company (as defined by Rule 12b-2
of the Exchange Act:  Yes [   ]   No
[X].





As of
October 27, 2008 there were 14,050,500 shares of Common Stock of the issuer
outstanding.





TABLE OF
CONTENTS





PART
      I FINANCIAL STATEMENTSItem
      1
            Financial
      Statements
            2Item
      2
            Management's
      Discussion and Analysis or Plan of Operation
            7PART
      II OTHER INFORMATIONItem
      1
            Legal
      Proceedings
            12Item
      2
            Changes
      in Securities
            12Item
      3
            Default
      upon Senior Securities
            12Item
      4
            Submission
      of Matters to a Vote of Security Holders
            12Item
      5
            Other
      Information
            12Item
      6
            Exhibits
      and Reports on Form 8-K
            12








i


TRIPLE
      A MEDICAL, INC.CONSOLIDATED
      BALANCE SHEETSSEPTEMBER
      30, 2008 AND DECEMBER 31, 2007(Unaudited)ASSETSSeptember
      30, 2008
            
            
            December
      31, 2007CURRENT
      ASSETS:Cash
            
            $
            66,759
            
            
            $
            270,906Accounts
      receivable
            
            
            97,919
            
            
            
            -Other
      receivables
            
            
            20,121
            
            
            
            1,100Prepaid
      expenses
            
            
            -
            
            
            
            29,363Total
      current assets
            
            
            184,799
            
            
            
            301,369Computer
      equipment, net
            
            
            21,216
            
            
            
            23,270Developed
      software, net
            
            
            343,421
            
            
            
            362,549TOTAL
      ASSETS
            
            $
            549,436
            
            
            $
            687,188LIABILITIES AND STOCKHOLDERS'
      EQUITYCURRENT
      LIABILITIES:Accounts
      payable and accrued expenses
            
            $
            32,461
            
            
            $
            67,756STOCKHOLDERS'
      EQUITYPreferred
      stock, $0.01 par value, 20,000,000 authorized,-0-  issued
      and outstanding
            
            
            -
            
            
            
            -Common
      stock, $0.01 par value, 50,000,000 authorized,14,050,500
      and 13,744,000 issued and outstanding, respectively
            
            
            14,050
            
            
            
            13,744Additional
      paid-in-capital
            
            
            1,550,699
            
            
            
            1,258,756Subscription
      receivable
            
            
            (2,000
            )
            
            
            -Accumulated
      deficit
            
            
            (1,045,774
            )
            
            
            (653,068
            )Total
      stockholders’ equity
            
            
            516,975
            
            
            
            619,432TOTAL
      LIABILITIES AND STOCKHOLDERS' EQUITY
            
            $
            549,436
            
            
            $
            687,188See
      accompanying summary of accounting policies and notes to consolidated
      financial statements.


2


TRIPLE
      A MEDICAL, INC.CONSOLIDATED
      STATEMENTS OF OPERATIONSFor
      the Three and Nine Months Ended September 30, 2008 and
      2007(Unaudited)Three
      Months Ended
            
            
            Three
      Months Ended
            
            
            Nine Months
      Ended
            
            
            NineMonths
      EndedSeptember 30,
      2008
            
            
            September 30,
      2007
            
            
            September30,
      2008
            
            
            September 30,
      2007REVENUE
            
            $
            37,605
            
            
            $
            85,812
            
            
            $
            458,461
            
            
            $
            85,812OPERATING
      EXPENSES:Depreciation
      and amortization
            
            
            7,061
            
            
            
            -
            
            
            
            21,182
            
            
            
            -Selling,
      general and administrative
            
            
            224,954
            
            
            
            87,645
            
            
            
            823,458
            
            
            
            105,707Software
      development costs
            
            
            7,582
            
            
            
            40,040
            
            
            
            8,810
            
            
            
            275,457Total
      operating expenses
            
            
            239,597
            
            
            
            127,685
            
            
            
            853,450
            
            
            
            381,164Los
      from oprations
            
            
            (201,915)
            
            
            
            (41,873)
            
            
            
            (394,989)
            
            
            
            (295,532)OTHER
      INCOMEInterest
      income
            
            
            77
            
            
            
            382
            
            
            
            2,283
            
            
            
            4,428Net
      loss
            
            $
            (201,915
            )
            
            $
            (41,541
            )
            
            $
            (392,706
            )
            
            $
            (290,924
            )Basic
      and diluted weighted average shares outstanding
            
            
            14,050,500
            
            
            
            13,500,000
            
            
            
            13,992,734
            
            
            
            13,500,000Basic
      and diluted net loss per share
            
            $
            (0.01
            )
            
            $
            (0.00
            )
            
            $
            (0.03
            )
            
            $
            (0.02
            )   See
accompanying summary of accounting policies and notes to consolidated financial
statements.


3


TRIPLE
      A MEDICAL, INC.CONSOLIDATED
      STATEMENTS OF STOCKHOLDERS' EQUITYFor
      the Year Ended December 31, 2007 and the Nine Months Ended September 30,
      2008(Unaudited)AdditionalCommon
            
            
            Common
            
            
            Paid
      In
            
            
            Subscription
            
            
            AccumulatedShares
            
            
            Amount
            
            
            Capital
            
            
            Receivable
            
            
            Deficit
            
            
            TotalBalance  December
      31, 2006
            
            
            13,500,000
            
            
            $
            13,500
            
            
            $
            753,000
            
            
            $
            -
            
            
            $
            (154,446
            )
            
            $
            612,054Contributed
      capital
            
            
            -
            
            
            
            -
            
            
            
            376,000
            
            
            
            -
            
            
            
            -
            
            
            
            376,000Imputed
      rent
            
            
            -
            
            
            
            -
            
            
            
            8,000
            
            
            
            -
            
            
            
            -
            
            
            
            8,000Cash
      received for stock
            
            
            244,000
            
            
            
            244
            
            
            
            121,756
            
            
            
            -
            
            
            
            -
            
            
            
            122,000Net
      loss
            
            
            -
            
            
            
            -
            
            
            
            -
            
            
            
            -
            
            
            
            (498,622
            )
            
            
            (498,622
            )Balance  December
      31, 2007
            
            
            13,744,000
            
            
            
            13,744
            
            
            
            1,258,756
            
            
            
            -
            
            
            
            (653,068
            )
            
            
            619,432Contributed
      capital
            
            
            -
            
            
            
            -
            
            
            
            137,000
            
            
            
            -
            
            
            
            -
            
            
            
            137,000Imputed
      rent
            
            
            -
            
            
            
            -
            
            
            
            2,000
            
            
            
            -
            
            
            
            -
            
            
            
            2,000Cash
      received for stock
            
            
            276,500
            
            
            
            276
            
            
            
            137,973
            
            
            
            (2,000
            )
            
            
            -
            
            
            
            136,249Stock
      issued for services
            
            
            30,000
            
            
            
            30
            
            
            
            14,970
            
            
            
            -
            
            
            
            -
            
            
            
            15,000Net
      loss
            
            
            -
            
            
            
            -
            
            
            
            -
            
            
            
            -
            
            
            
            (392,706
            
            
            
            (392,706
            )Balance  September
      30, 2008
            
            
            14,050,500
            
            
            $
            14,050
            
            
            $
            1,550,699
            
            
            $
            (2,000
            )
            
            $
            (1,045,774
            )
            
            $
            516,975See
      accompanying summary of accounting policies and notes to consolidated
      financial statements.








4


TRIPLE
      A MEDICAL, INC.CONSOLIDATED
      STATEMENTS OF CASH FLOWSFor
      the Nine Months Ended September 30, 2008 and 2007(Unaudited)Nine
      Months Ended
            
            
            Nine
      Months EndedSeptember
      30, 2008
            
            
            September
      30, 2007CASH
      FLOWS FROM OPERATING ACTIVITIES:Net
      loss
            
            $
            (392,706
            )
            
            $
            (290,924
            )Adjustments
      to reconcile net loss to netcash
      used in operating activities:Depreciation
      and amortization
            
            
            21,182
            
            
            
            -Change
      in accounts receivable
            
            
            (97,919
            )
            
            
            -Change
      in other receivables
            
            
            (19,021
            )
            
            
            -Stock
      issued for services
            
            
            15,000
            
            
            
            -Imputed
      rent
            
            
            2,000
            
            
            
            4,000Prepaid
      expenses and other current assets
            
            
            29,363
            
            
            
            -Change
      in accounts payable and accrued expenses
            
            
            (35,295
            )
            
            
            (15,263
            )NET
      CASH USED IN OPERATING ACTIVITIES
            
            
            (477,396
            )
            
            
            (302,187
            )CASH
      FLOWS FROM FINANCING ACTIVITIES:Proceeds
      from sale of stock
            
            
            136,249
            
            
            
            -Contributed
      capital
            
            
            137,000
            
            
            
            108,000NET
      CASH PROVIDED BY FINANCING ACTIVITIES
            
            
            273,249
            
            
            
            108,000NET
      DECREASE IN CASH
            
            
            (204,147
            )
            
            
            (194,187
            )CASH,
      BEGINNING OF PERIOD
            
            
            270,906
            
            
            
            265,728CASH,
      END OF PERIOD
            
            $
            66,759
            
            
            $
            71,541NON-CASH
      TRANSACTIONSCommon
      stock issued for subscription receivable
            
            $
            2,000
            
            
            $
            -SUPPLEMENTAL
      DISCLOSURESInterest
      paid
            
            $
            -
            
            
            $
            -Income
      taxes paid
            
            $
            -
            
            
            $
            -See
      accompanying summary of accounting policies and notes to consolidated
      financial statements.


5





TRIPLE
A MEDICAL, INC.





Notes to
the Consolidated Financial Statements


September
30, 2008











NOTE 1--BASIS OF
PRESENTATION





The
accompanying unaudited interim consolidated financial statements of Triple A
Medical, Inc. (“Triple A”) have been prepared in accordance with accounting
principles generally accepted in the United States of America for interim
financial information and with the rules and regulations of the Securities and
Exchange Commission.  They do not include all information and notes
required by U.S. generally accepted accounting principles for complete financial
statements.  These interim consolidated financial statements should be read
in conjunction with the audited consolidated financial statements and the
accompanying notes contained in Triple A’s Annual Report on Form 10-K filed on
April 10, 2008 for the year ended December 31, 2007.





In the
opinion of management, all adjustments (consisting of normal recurring accruals)
considered necessary for a fair presentation of the financial position, results
of operations and cash flows for the interim periods presented have been
included.  The results of operations for interim periods are not
necessarily indicative of the results that may be expected for any other interim
period or for the full year.





The
preparation of consolidated financial statements in conformity with accounting
principles generally accepted in the U.S. requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period.  Actual results could differ from those
estimates.





NOTE 2--STOCK BASED
COMPENSATION





Triple A
adopted SFAS No. 123(R), on January 1, 2008.  SFAS 123(R)
requires companies to measure the cost of employee services received in exchange
for an award of an equity instrument based on the grant-date fair value of the
award.  We account for non-employee share-based awards in accordance
with EITF No. 96-18, “Accounting for Equity Instruments That Are
Issued to Other Than Employees for Acquisition, or in Conjunction with Selling,
Goods or Services.”  During the three months ended September 30, 2008,
Triple A did not issue shares for services, but issued 30,000 shares for
services valued at $15,000 for the nine months ended September 30,
2008.





NOTE 3--GOING
CONCERN





Triple
A's financial statements have been presented on the basis that it is a going
concern, which contemplates the realization of assets and the satisfaction of
liabilities in the normal course of business.  Triple A has recurring
losses and an accumulated deficit.  Additionally, Triple A has
incurred recurring deficits in cash flows from operating
activities.








6





Triple A's ability to continue as a
going concern is dependent upon its ability to successfully market and implement
its developed software product and to achieve profitable
operations.  The accompanying financial statements do not include any
adjustments that might result from the outcome of these
uncertainties.





NOTE 4--RELATED PARTY
TRANSACTIONS





In order
to fund the development of the software, Triple A entered into an ‘Investment
and Net Revenue Agreement’ with Phoenix Ortho, LLC (ORTHO), an entity controlled
by a relative of the President of Triple A.  In connection with this
agreement, ORTHO provided Triple A $745,000 during 2006, $108,000 in 2007, and
$137,000 in the nine months ended 2008.  This cash is reflected as
additional paid-in capital as of September 30, 2008, and December 31, 2007 and
2006.  In exchange for this contributed capital, Triple A provided
ORTHO with an income participation interest in its operations.  The
terms of this agreement require Triple A to pay ORTHO 33.1% of the net revenues
generated by the business in the immediately preceding month.





In the
third quarter of 2008, Triple A borrowed $10,000 from ORTHO to help fund
operations.  This balance is included in Accounts
Payable.





In
addition, office space has been contributed by related parties from January 1
thru March 31, 2008 rent-free.  Two thousand of expense has been
imputed related to this office space in the first quarter of 2008.  In
the nine months ended September 30, 2008, the Company paid a related party
$24,000 for office space rent.





NOTE 5-RECENTLY ADOPTED
ACCOUNTING PROUNCEMENTS





Tripe A
does not anticipate an recently issued accouitng pronouncement to have an impact
of its financial statements





Item
2.  MANAGEMENT’S DISCUSSION AND ANALYSIS





This
report contains forward looking statements within the meaning of Section 27A of
the Securities Act of 1933, as amended and Section 21E of the Securities
Exchange Act of 1934, as amended.  The Company’s actual results could
differ materially from those set forth on the forward looking statements as a
result of the risks set forth in the Company’s filings with the Securities and
Exchange Commission, general economic conditions, and changes in the assumptions
used in making such forward looking statements.





General





The
Company was founded to create electronic healthcare software
applications.  The initial development is an Electronic Health Record
(EHR), specifically designed to meet the needs of orthopedic physicians. For the
past four years, our President, Morgan McCune, has worked directly with dozens
of orthopedic physicians in more than 40 states.  He has reviewed
orthopedic clinical research and extensively surveyed reference
materials.  Based upon the research, Mr. McCune created a database
with a graphical interface to assist orthopedic physicians with the
documentation of the patient encounter.








7





The
Market





Phoenix
Ortho is participating in an $18 billion market for Electronic Health Records
(EHR).  The Orthopedics market approaches $2 billion.  There
are more than 20,500 board certified orthopedists and 12,872 orthopedic group
practices.  Research indicates that this market is less than 10%
penetrated.  Recent surveys indicate that 58% of medical practices are
looking at purchasing an EHR in the next two years.  In 2005 the
average orthopedic EHR sale was $171,000. (2001 AAOS Census, 2004 MGMA
Survey)  Recent growth rate in new sales has averaged about
30%.  We expected this growth rate will accelerate sharply over the
next two years.





Keys
to Success





Focus: We believe focus is the
essential ingredient to successful EHR development and deployment. Phoenix Ortho
is unique in its extensive experience and singular focus on
orthopedics.  By focusing on one specialty, we can avoid the wholesale
generalities that have plagued EHR vendors and frustrated their orthopedic
clients.  Phoenix Ortho understands the unique requirements of
orthopedic physicians.  Focus promotes the creation of relevant
content and specialty specific application functionality.  Content
relevance is a significant factor in physician adoption.





In
mid-2007 we began marketing our new orthopedic EHR software.  The new
project was focused on resolving the key problems that have historically posed
barriers to adoption, successful implementation, and client
satisfaction.  These obstacles can be grouped together in four
categories; Product Functionality, Product Implementation, Product Support, and
Product Acquisition Cost.





Product Functionality:The
software will establishnew standards for ease
of use, efficiency, stability, and availability facilitating end user
adoption.  The software is designed and scaled specifically for the
pen tablet environment.  We believe the pen tablet is the device of
choice for EHR end users.  Our development will utilize input tools
such as sliders, combo boxes, role over images and other custom designed tools
to provide a truly keyboard free interface.  Other tablet input
options such as “Pen and Ink” and “Voice to Text” will be available as needed to
capture representative content.  The ODClient will improve stability,
performance, and availability by utilizing .NET automatic versioning and
auto-recovery from deadlock errors and memory leaks.  Advanced
compilation and caching techniques substantially lower CPU
utilization.  The ODClient (smart client) will support both
disconnected and low bandwidth clients supporting end user mobility and
minimizing the frustration of “Systems Down”.





Product Implementation:We
have developed an orthopedic, client focused implementation methodology we call
the “AAA” implementation plan.  This plan focuses on the three
critical aspects of implementation; Assessment, Adoption, and
Adaptation.  All implementations will begin with
Assessment.  During the assessment phase the unique needs of the end
users are identified.  Each user is profiled to determine their needs
and potential road blocks to success.  The physicians are identified
as Champions, Contenders, or Challengers.  An implementation strategy
is designed around these “Adoption Profiles”.  The Champions are the
eager adopters and should be the first users.  The Contenders are
frequently indifferent but, usually agreeable adopters.  The
Challengers represent approximately 30% of the physicians who will resist
implementation for a variety of reasons.  Sometimes they feel they are
too technology challenged and fearful, some are too busy and may fear loss of
revenue by adoption, while others are just resistant to anything
new.  When these objections are clearly understood, “Adaptation” can
take place and in most cases mitigate the Challengers
objection(s).  Adaptation is the process of introducing (training) the
end users to the application “Best Practices”.  It also takes into
account the “Profile” of the end user to create a “Best Practices” by provider
(See Challengers above).










8





Product Support:The ODClient
on the .NET framework makes it easier than ever to update and deploy new
applications.  Thanks to intelligent, one touch updates and
intelligent support client PCs can be updated by copying the application to the
target directory.  Client PCs may be updated automatically with no
interruption or the may be updated on demand.





Product Acquisition Cost:Wewill
provide alternative acquisition models to help overcome purchase resistance due
to capital costs.  Although we will make the EHR software available on
the traditional for- purchase basis, through our innovative 3-Tier ODClient
architecture we will also offer a service based model.  Our customers
will be able to utilize the full function and features of the EHR software for
an affordable monthly service charge.





Utilizing
their extensive experience and knowledge of orthopedics, coupled with state of
the art rapid development tools, we believe these obstacles can be overcome and
their goals are achievable.  The recent completion of their fully
functional prototype, suggests that their development strategies are on
track.





Technology
Overview





For many
technologists and software developers, 2006 is a “watershed
year.”  With the official release of Visual Studio 2005, providing a
seamless integration between C#, the .Net Framework 2.0 and SQL Server 2005, a
new paradigm for software development has arrived.  According to Bill
Gates “the transition to .NET is as dramatic as the move from MS-DOS to
Windows.”  The emergence of these companion technologies has created
an opportunity for rapid development, application flexibility, architectural
mobility, simplified deployment and support/updates that did not exist prior to
November 2005.





We are
positioned to take full advantage of this shifting technological
paradigm.  The software is the first orthopedic EHR to be developed
utilizing innovative 3-Tier architecture on SQL 2005, the .NET framework, C#,
Visual Studio 2005 and the Microsoft Enterprise Library.





Implementation
of 3-Tier Architecture





ODClient:Combines the best of
traditional rich client functionality with the ease of thin client deployment
and maintenance.  ODClient raises the standard by adding support for
mobile, offline or low bandwidth users with intelligent connection management
(data caching and batch requests).  Even fully connected clients will
see performance and stability benefits.  ODClient will reduce
management costs by avoiding the complexities and “application fragility” of
traditional rich client deployments (shared code, registered components, and
DLLs in a common folder).  ODClient will utilize a seamless,
simplified, predictable “no touch deployment”.  Updates may occur in
the background or on demand. Tools: Visual C# 2005, Microsoft Office 2003, and
XML underlying structure.





Application Server Tier:Business-objects that implement the business rules reside
here.  This tier isolates the data from direct access by the
clients.  Tools: .Net Framework 2.0 and Microsoft Enterprise
Library.





Data Server Tier: This tier is
responsible for data storage.  SQL Server 2005 with .NET integration
is the database of choice.  However, the 3-Tier architecture supports
application portability and database independence.  Tools: SQL Server
2005, T-SQL, CLR Execution Environment, .Net Code Integration, Business
Intelligence, Indexed, and Full Text Search.










9





Mission





We
develop, document, and market EHR solutions that are efficient, intuitive, easy
to use, and promote physician acceptance.  This software will reduce
the cost and risks associated with manual paper based systems.  This
will in turn improve the quality of care by more completely documenting patient
care, eliminating common errors and tracking relevant procedures, events, and
outcomes.  The EHR will provide an excellent ROI to the physician by
reducing costs and enhancing revenues do to improved documentation and optimal
billable code levels.





Conclusion





The
orthopedic EHR market is emerging rapidly with nearly $2 billion in potential
sales.  We believe that our software is uniquely positioned to fill a
substantial void in the orthopedic vertical market for EHR.Our extensive orthopedic
experience, our singular focus, our dedicated, proactive approach to training,
implementation and support, coupled with our utilization of state of the art
development tools will distinguish us from every alternative EHR in the
orthopedic vertical market space.  The result will be a uniquely
relevant orthopedic encounter management solution that is efficient, intuitive,
easy to use, and promotes physician acceptance.  We expect this EHR to
be well received, quickly adopted, and widely endorsed by the orthopedic
community.





RESULTS
FOR THE FISCAL QUARTER ENDED September 30, 2008





During
the nine months ended September 30, 2008, we had continued marketing our
software and following up on sales leads which had been generated throughout
2007 and into 2008.  The sales cycle can be anywhere from three months
to one year.  In addition to a couple independent sales persons and
alliances with marketing partners, we hired a full time salesman on commission
only.  Our sales leads continue to be generated and followed up on as
we receive them from our own efforts by attendance at trade shows and from
referrals from our industry cross marketing agreements.  In addition,
we expect to see sales from our full time salesman starting in the last quarter
of 2008 into the first quarter of 2009.





REVENUE.
Revenue in the three months ended September 30, 2008 was $37,605 compared to
$85,812 in the three months ended September 30, 2007.  The reduction
is attributable to the timing of installations where in 2007, Q3 was the first
month of sales, and in 2008, installation contracts were signed and completed in
Q2.  Revenue in Q3 2008, has been mainly service
related.  Our revenue for the nine months ended September 30, 2008 was
$458,461 compared to $85,812 in the same nine months of 2007.  The
increase is due to the contract installations mainly in the first and second
quarters of 2008.





EXPENSES.
Depreciation and amortization expense was $7,061 for the three months ended
September 30, 2008 and $21,182 for the nine months ended September 30, 2008
where in the same periods of 2007 it was zero.


Software
development costs totaled $6,983 for the three months ended September 30, 2008
compared to $40,040 for the same three months in 2007 and $8,211 and $275,457
for the nine months ended September 30, 2008 and 2007,
respectively.  The significant decrease was due to the capitalization
of many of the software development costs in 2007, where in 2008 our software
was basically complete and we were marketing and installing it.


Other
selling, general and administrative costs were $225,553 and $87,645 for the
three months ended September 30, 2008 and 2007, respectively, and $824,057 and
$105,707 for the nine months ended September 30, 2008 and 2007,
respectively.  The significant increase was due to most costs in the
first quarter of 2007 associated with the development of our software, were
capitalized, and secondly, in 2008 we were marketing, installing, and supporting
our software and in order to do this effectively.  We have added a
number of support personnel to install and support our software.





OTHER
INCOME. We had interest income of $77 and $332 for the three months ended
September 30, 2008 and 2007, respectively, and interest income of $2,283 and
$4,428 for the nine months ended September 30, 2008 and 2007,
respectively.





NET LOSS.
Net loss for the three months ended September 30, 2008 was ($201,915) compared
to a net loss of ($41,541) for the three months ended September 30,
2007.  Net loss for the nine months ended September 30, 2008 was
($392,706) compared to a net loss of ($290,924) for the nine months ended
September 30, 2007.








10





LIQUIDITY
AND CAPITAL RESOURCES. Our cash balance at September 30, 2008 was $66,759 which
we believe will be sufficient liquidity to carry us to the point where all of
our software will provide enough cash flow to internally fund our
operations.





Employees





As of
September 30, 2008, the Company had nine employees which it pays through an
employee leasing agreement.  Four of the employees are support and/or
technical personnel.





ITEM 3:
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK




Not
applicable.





ITEM 4:
CONTROLS AND PROCEDURES




We
carried out an evaluation of the effectiveness of the design and operation of
our disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) as of September 30, 2008.  This
evaluation was accomplished under the supervision and with the participation of
our chief executive officer / principal executive officer, and chief financial
officer / principal financial officer who concluded that our disclosure controls
and procedures are not effective to ensure that all material information
required to be filed in the quarterly Form 10-Q has been made known to
them.




For
purposes of this section, the term disclosure controls and procedures means
controls and other procedures of an issuer that are designed to ensure that
information required to be disclosed by the issuer in the reports that it files
or submits under the Act (15 U.S.C. 78a et seg.) is recorded, processed,
summarized and reported, within the time periods specified in the Commission’s
rules and forms.  Disclosure, controls and procedures include, without
limitation, controls and procedures designed to ensure that information required
to be disclosed by in our reports filed under the Securities Exchange Act of
1934, as amended (the "Act") is accumulated and communicated to the issuer's
management, including its principal executive and principal financial officers,
or persons performing similar functions, as appropriate to allow timely
decisions regarding required disclosure.




Based
upon an evaluation conducted for the period ended September 30, 2008, our Chief
Executive and Chief Financial Officer as of September 30, 2008 and as of the
date of this Report, has concluded that as of the end of the periods covered by
this report, we have identified the following material weakness of our internal
controls:




·
            Reliance
      upon independent financial reporting consultants for review of critical
      accounting areas and disclosures and material non-standard
      transaction.




·
            Lack
      of sufficient accounting staff which results in a lack of segregation of
      duties necessary for a good system of internal
  control.




In order
to remedy our existing internal control deficiencies, as our finances allow, we
will hire additional accounting staff.




Changes in Internal Controls
over Financial Reporting




We have
not yet made any changes in our internal controls over financial reporting that
occurred during the period covered by this report on Form 10-Q/A that has
materially affected, or is reasonably likely to materially affect, our
internal control over financial reporting.


11


PART
II





Items No.
1, 2, 3, 4, 5 - Not Applicable.








Item No.
6 - Exhibits and Reports on Form 8-K





(a) No
reports on Form 8-K were filed during the three months ended September 30,
2008.





(b)   Exhibits





Exhibit
Number                                                      Name
of Exhibit





31.1           Certification
of Chief Executive Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as
enacted by Section 302 of the Sarbanes-Oxley Act of 2002.





31.2           Certification
of Chief Financial Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as
enacted by Section 302 of the Sarbanes-Oxley Act of 2002.





32.1           Certification
of Chief Executive Officer and Chief Financial Officer, pursuant to 18 United
States Code Section 1350, as enacted by Section 906 of the Sarbanes-Oxley Act of
2002.











SIGNATURES





In
accordance with the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.





TRIPLE A
MEDICAL, INC.





By /s/ P. Morgan
McCune





P. Morgan
McCune, President, CFO





Date:
November 1, 2008








12